Pfizer Inc.PFENYSE

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem.

fool.com

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026

Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens in 2026, though, Vertex and Medtronic have attractive prospects.

feeds.benzinga.com

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.

gurufocus.com

Pfizer Turns To AI Where Drug Risk Is Highest

Pfizer (PFE) is taking a more hands-on approach to AI in drug research, teaming up with startup Boltz to help its scientists make smarter calls earlier in the d

gurufocus.com

Pfizer Partners with Boltz to Use AI in Drug Discovery

Pfizer Inc. (PFE, Financials) has teamed up with Boltz to add the biotech company's biomolecular AI models to its research pipeline. This will help speed up the

fool.com

Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks

Some safe dividend stocks also offer high yields. Their payouts are high but aren't risky, and are backed by strong fundamentals.

247wallst.com

Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today

Federal Reserve Governor Stephen Miran, whose term ends on January 31, argued in a recent Fox Business interview that the Fed should implement well over 100 basis points (or one percentage point) of rate cuts this year to support economic growth.

businesswire.com

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity.

defenseworld.net

Cerity Partners LLC Reduces Stake in Pfizer Inc. $PFE

Cerity Partners LLC trimmed its position in Pfizer Inc. (NYSE: PFE) by 5.3% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,738,649 shares of the biopharmaceutical company's stock after selling 97,684 shares during the period. Cerity Partners LLC's holdings in Pfizer were worth

fool.com

Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year.

fool.com

3 Drug Stocks to Buy at a Discount

Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.

businesswire.com

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hearing took place within days of the The US Food and Drug Administration (FDA) approving a label change to Pfizer's contr.

fool.com

This Could Be Key to Pfizer's Turnaround in 2026

Pfizer has been making deals in recent years to enhance its long-term growth potential. Last month, it reached a GLP-1 licensing deal with a China-based drug company.

seekingalpha.com

Quant Q&A With Steven Cress

Steven Cress answers your questions! Credo Technology maintains A+ momentum rating, outperforming its sector across multiple timeframes despite recent stagnation concerns.

schaeffersresearch.com

Dow Snags Another Record as Amazon Stock Leads Gains

Stocks are moving higher, with the Dow Jones Industrial Average (DJI) enjoying a fresh record high

marketwatch.com

America's new vaccine doctrine for children replaces data with dogma

In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sold as a victory for “individual choice.

zacks.com

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

businesswire.com

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identif.

defenseworld.net

Pfizer Inc. $PFE Position Cut by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its position in shares of Pfizer Inc. (NYSE: PFE) by 9.1% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 3,803,506 shares of the biopharmaceutical company's stock after selling 380,452 shares during the period. Commonwealth Equity Services LLC owned 0.07% of

fool.com

5 of the Safest Ultra-High-Yield Dividend Stocks You Can Confidently Buy for 2026

Five sensational income stocks -- sporting yields ranging from 5.3% to 13.1% -- can fatten investors' pocketbooks in the new year.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance